Zebrafish Experimental Animal Models for AD: A Comprehensive
Review

Ruksar      Sande; Angel      Godad; Gaurav      Doshi
doi:10.2174/0127724328279684240104094257
Abstract

AD disease (AD) is a multifaceted and intricate neurodegenerative disorder characterized by intracellular neurofibrillary tangle (NFT) formation and the excessive production and deposition of Aβ senile plaques. While transgenic AD models have been found instrumental in unravelling AD pathogenesis, they involve cost and time constraints during the preclinical phase. Zebrafish, owing to their simplicity, well-defined behavioural patterns, and relevance to neurodegenerative research, have emerged as a promising complementary model. Zebrafish possess glutaminergic and cholinergic pathways implicated in learning and memory, actively contributing to our understanding of neural transmission processes. This review sheds light on the molecular mechanisms by which various neurotoxic agents, including okadaic acid (OKA), cigarette smoke extract, metals, and transgenic zebrafish models with genetic similarities to AD patients, induce cognitive impairments and neuronal degeneration in mammalian systems. These insights may facilitate the identification of effective neurotoxic agents for replicating AD pathogenesis in the zebrafish brain. In this comprehensive review, the pivotal role of zebrafish models in advancing our comprehension of AD is emphasized. These models hold immense potential for shaping future research directions and clinical interventions, ultimately contributing to the development of novel AD therapies.
Keywords: AD, neurodegeneration, neurofibrillary tangles, amyloid β plaques, cognitive impairment agents, transgenic models.
[1]
Scheltens P, Blennow K, Breteler MMB, et al. Alzheimer’s disease. Lancet  2016; 388(10043): 505-17.
 [http://dx.doi.org/10.1016/S0140-6736(15)01124-1] [PMID: 26921134]

[2]
Lleó A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer’s disease. Annu Rev Med  2006; 57(1): 513-33.
 [http://dx.doi.org/10.1146/annurev.med.57.121304.131442] [PMID: 16409164]

[3]
Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer’s Disease therapy and prevention strategies. Annu Rev Med  2017; 68: 413-30.
 [http://dx.doi.org/10.1146/annurev-med-042915-103753]

[4]
Bhattacharjee S, Zhao Y, Hill JM, Percy ME, Lukiw WJ. Aluminum and its potential contribution to Alzheimer’s disease (AD). Front Aging Neurosci  2014; 6: 62.
 [http://dx.doi.org/10.3389/fnagi.2014.00062] [PMID: 24782759]

[5]
Wu L, Rosa-Neto P, Hsiung GYR, et al. Early-onset familial Alzheimer’s disease (EOFAD). Can J Neurol Sci  2012; 39(4): 436-45.
 [http://dx.doi.org/10.1017/S0317167100013949] [PMID: 22728850]

[6]
Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum Mol Genet  2010; 19(R1): R12-20.
 [http://dx.doi.org/10.1093/hmg/ddq160] [PMID: 20413653]

[7]
Arnsten AFT, Datta D, Del Tredici K, Braak H. Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer’s disease. Alzheimers Dement  2021; 17(1): 115-24.
 [http://dx.doi.org/10.1002/alz.12192] [PMID: 33075193]

[8]
Tcw J, Goate AM. Genetics of β-amyloid precursor protein in alzheimer’s disease. Cold Spring Harb Perspect Med  2017; 7(6): a024539.
 [http://dx.doi.org/10.1101/cshperspect.a024539]

[9]
Pogue AI, Lukiw WJ. Aluminum, the genetic apparatus of the human CNS and Alzheimer’s disease (AD). Morphologie  2016; 100(329): 56-64.
 [http://dx.doi.org/10.1016/j.morpho.2016.01.001] [PMID: 26969391]

[10]
Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer’s disease. Nat Rev Drug Discov  2013; 12(4): 324.
 [http://dx.doi.org/10.1038/nrd3842-c1] [PMID: 23493086]

[11]
Hampel H, Hardy J, Blennow K, et al. The amyloid-β pathway in alzheimer’s Disease. Mol Psychiatry  2021; 26(10): 5481-503.
 [http://dx.doi.org/10.1038/s41380-021-01249-0] [PMID: 34456336]

[12]
Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH. The amyloid-β pathway in Alzheimer’s Disease. Mol Psychiatry  2021; 26(10): 5481-503.
 [http://dx.doi.org/10.1038/s41380-021-01249-0]

[13]
Alavi NSM, Soussi-Yanicostas N. Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies? Oxid Med Cell Longev  2015; 2015: 151979.
 [http://dx.doi.org/10.1155/2015/151979]

[14]
Brandt R, Léger J, Lee G. Interaction of tau with the neural plasma membrane mediated by tau’s amino-terminal projection domain. J Cell Biol  1995; 131(5): 1327-40.
 [http://dx.doi.org/10.1083/jcb.131.5.1327] [PMID: 8522593]

[15]
Rösler TW, Marvian A, Brendel M, et al. Four-repeat tauopathies. Prog Neurobiol  2019; 180: 101644.
 [http://dx.doi.org/10.1016/j.pneurobio.2019.101644] [PMID: 31238088]

[16]
Saha P, Sen N. Tauopathy: A common mechanism for neurodegeneration and brain aging. Mech Ageing Dev  2019; 178: 72-9.
 [http://dx.doi.org/10.1016/j.mad.2019.01.007] [PMID: 30668956]

[17]
Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer’s disease and the basal forebrain cholinergic system: Relations to β-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol  2002; 68(3): 209-45.
 [http://dx.doi.org/10.1016/S0301-0082(02)00079-5] [PMID: 12450488]

[18]
Lindsley CW, Hooker JM. Beyond the amyloid hypothesis of alzheimer’s disease: tau pathology takes center stage. ACS Chem Neurosci  2018; 9(11): 2519.
 [http://dx.doi.org/10.1021/acschemneuro.8b00610] [PMID: 30458619]

[19]
Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med  1996; 2(8): 864-70.
 [http://dx.doi.org/10.1038/nm0896-864] [PMID: 8705854]

[20]
Sengupta U, Nilson AN, Kayed R. The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy. EBioMedicine  2016; 6: 42-9.
 [http://dx.doi.org/10.1016/j.ebiom.2016.03.035] [PMID: 27211547]

[21]
Yuan S, Huang X, Zhang L, et al. Associations of air pollution with all-cause dementia, Alzheimer’s disease, and vascular dementia: A prospective cohort study based on 437,932 participants from the UK biobank. Front Neurosci  2023; 17: 1216686.
 [http://dx.doi.org/10.3389/fnins.2023.1216686] [PMID: 37600021]

[22]
Bagyinszky E, Youn YC, An SSA, Kim S. Mutations, associated with early-onset Alzheimer’s disease, discovered in Asian countries. Clin Interv Aging  2016; 11: 1467-88.
 [http://dx.doi.org/10.2147/CIA.S116218] [PMID: 27799753]

[23]
Adams JD. Probable causes of Alzheimer’s disease. Sci  2021; 3(1): 16.
 [http://dx.doi.org/10.3390/sci3010016]

[24]
Jiang T, Yu JT, Tian Y, Tan L. Epidemiology and etiology of Alzheimer’s disease: From genetic to non-genetic factors. Curr Alzheimer Res  2013; 10(8): 852-67.
 [http://dx.doi.org/10.2174/15672050113109990155] [PMID: 23919770]

[25]
Drummond E, Wisniewski T. Alzheimer’s Disease: Experimental models and reality. Acta Neuropathol  2017; 133(2): 155.

[26]
Yokoyama M, Kobayashi H, Tatsumi L, Tomita T. Mouse models of alzheimer’s disease. Front Mol Neurosci  2022; 15: 912995.
 [http://dx.doi.org/10.3389/fnmol.2022.912995] [PMID: 35799899]

[27]
Castillo-Rangel C, Marín G, Diaz-Chiguer DL, Zarate-Calderon CJ, Viveros-Martinez I, Caycho-Salazar FDMDJ. Animal models in Alzheimer’s disease: Biological plausibility and mood disorders. Neurology Perspectives  2023; 3(1): 100110.

[28]
Sasaguri H, Hashimoto S, Watamura N, et al. Recent advances in the modeling of alzheimer’s disease. Front Neurosci  2022; 16: 807473.
 [http://dx.doi.org/10.3389/fnins.2022.807473] [PMID: 35431779]

[29]
Vitek MP, Araujo JA, Fossel M, et al. Translational animal models for Alzheimer’s disease: An Alzheimer’s Association Business Consortium Think Tank. Alzheimers Dement  2020; 6(1): e12114.
 [http://dx.doi.org/10.1002/trc2.12114] [PMID: 33457489]

[30]
Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med  2010; 16(11): 1210-4.
 [http://dx.doi.org/10.1038/nm.2224]

[31]
Xu QQ, Yang W, Zhong M, Lin ZX, Gray NE, Xian YF. Animal models of Alzheimer’s disease: preclinical insights and challenges. Acta Materia Medica  2023; 2(2): 192-215.
 [http://dx.doi.org/10.15212/AMM-2023-0001]

[32]
Van Norman GA. Limitations of animal studies for predicting toxicity in clinical trials. JACC Basic Transl Sci  2019; 4(7): 845-54.
 [http://dx.doi.org/10.1016/j.jacbts.2019.10.008] [PMID: 31998852]

[33]
Newman M, Verdile G, Martins RN, Lardelli M. Zebrafish as a tool in Alzheimer’s disease research. Biochim Biophys Acta Mol Basis Dis  2011; 1812(3): 346-52.
 [http://dx.doi.org/10.1016/j.bbadis.2010.09.012]

[34]
Sanchez-Varo R, Mejias-Ortega M, Fernandez-Valenzuela JJ, Nuñez-Diaz C, Caceres-Palomo L, Vegas-Gomez L. Transgenic mouse models of alzheimer’s disease: An integrative analysis. Int J Mol Sci  2022; 23(10): 5404.

[35]
Bailone RL, Fukushima HCS, Fernandes BH, et al. Zebrafish as an alternative animal model in human and animal vaccination research. Lab Anim Res  2020; 36(1): 13.
 [http://dx.doi.org/10.1186/s42826-020-00042-4] [PMID: 32382525]

[36]
Shenoy A, Banerjee M, Upadhya A, Bagwe-Parab S, Kaur G. The brilliance of the zebrafish model: Perception on behavior and alzheimer’s Disease. Front Behav Neurosci  2022; 16: 861155.
 [http://dx.doi.org/10.3389/fnbeh.2022.861155] [PMID: 35769627]

[37]
Saleem S, Kannan RR. Zebrafish: An emerging real-time model system to study Alzheimer’s disease and neurospecific drug discovery. Cell Death Discov  2018; 4: 45.
 [http://dx.doi.org/10.1038/s41420-018-0109-7]

[38]
Santana S, Rico EP, Burgos JS. Can zebrafish be used as animal model to study Alzheimer’s disease? Am J Neurodegener Dis  2012; 1(1): 32.

[39]
Panula P, Sallinen V, Sundvik M, Kolehmainen J, Torkko V, Tiittula A. Modulatory neurotransmitter systems and behavior: Towards zebrafish models of neurodegenerative diseases. Zebrafish  2006; 3(2): 235-47.

[40]
Saleem S, Kannan RR. Zebrafish: An emerging real-time model system to study Alzheimer’s disease and neurospecific drug discovery. Cell Death Discov  2018; 4: 45.
 [http://dx.doi.org/10.1038/s41420-018-0109-7]

[41]
Chakraborty C, Hsu C, Wen Z, Lin C, Agoramoorthy G. Zebrafish: A complete animal model for in vivo drug discovery and development. Curr Drug Metab  2009; 10(2): 116-24.
 [http://dx.doi.org/10.2174/138920009787522197] [PMID: 19275547]

[42]
Williams FE, Messer WS Jr. Muscarinic acetylcholine receptors in the brain of the zebrafish (Danio rerio) measured by radioligand binding techniques. Comp Biochem Physiol C Toxicol Pharmacol  2004; 137(4): 349-53.
 [http://dx.doi.org/10.1016/j.cca.2004.03.002] [PMID: 15228953]

[43]
Park E, Lee Y, Kim Y, Lee CJ. Cholinergic modulation of neural activity in the telencephalon of the zebrafish. Neurosci Lett  2008; 439(1): 79-83.
 [http://dx.doi.org/10.1016/j.neulet.2008.04.064] [PMID: 18501513]

[44]
Mans RA, Hinton KD, Payne CH, Powers GE, Scheuermann NL, Saint-Jean M. Cholinergic stimulation of the adult zebrafish brain induces phosphorylation of glycogen synthase kinase-3 β and extracellular signal-regulated kinase in the telencephalon. Front Mol Neurosci  2019; 12: 91.
 [http://dx.doi.org/10.3389/fnmol.2019.00091] [PMID: 31040768]

[45]
Chen X, Gays D, Santoro MM. Transgenic zebrafish. Methods Mol Biol  2016; 1464: 107-14.
 [http://dx.doi.org/10.1007/978-1-4939-3999-2_10] [PMID: 27858360]

[46]
Marvin JS, Borghuis BG, Tian L, Cichon J, Harnett MT, Akerboom J. An optimized fluorescent probe for visualizing glutamate neurotransmission. Nat Methods  2013; 10(2): 162-70.
 [http://dx.doi.org/10.1038/nmeth.2333]

[47]
MacDonald RB, Kashikar ND, Lagnado L, Harris WA. A novel tool to measure extracellular glutamate in the zebrafish nervous system in vivo. Zebrafish  2017; 14(3): 284-6.
 [http://dx.doi.org/10.1089/zeb.2016.1385] [PMID: 28027028]

[48]
Gesemann M, Maurer CM, Neuhauss SCF. Excitatory amino acid transporters in the zebrafish. Brain Res Bull  2010; 83(5): 202-6.
 [http://dx.doi.org/10.1016/j.brainresbull.2010.04.018] [PMID: 20466040]

[49]
Li F, Tsien JZ. Memory and the NMDA receptors. N Engl J Med  2009; 361(3): 302-3.
 [http://dx.doi.org/10.1056/NEJMcibr0902052]

[50]
Clemente D, Porteros Á, Weruaga E, et al. Cholinergic elements in the zebrafish central nervous system: Histochemical and immunohistochemical analysis. J Comp Neurol  2004; 474(1): 75-107.
 [http://dx.doi.org/10.1002/cne.20111] [PMID: 15156580]

[51]
Yegambaram M, Manivannan B, Beach T, Halden R. Role of environmental contaminants in the etiology of Alzheimer’s disease: A review. Curr Alzheimer Res  2015; 12(2): 116-46.
 [http://dx.doi.org/10.2174/1567205012666150204121719] [PMID: 25654508]

[52]
Kamat PK, Rai S, Swarnkar S, Shukla R, Nath C. Mechanism of synapse redox stress in Okadaic acid (ICV) induced memory impairment: Role of NMDA receptor. Neurochem Int  2014; 76: 32-41.
 [http://dx.doi.org/10.1016/j.neuint.2014.06.012] [PMID: 24984170]

[53]
Rudrabhatla P, Pant HC. Role of protein phosphatase 2A in Alzheimer’s disease. Curr Alzheimer Res  2011; 8(6): 623-32.
 [http://dx.doi.org/10.2174/156720511796717168] [PMID: 21605044]

[54]
Williams FE, Koehler D. Utilizing zebrafish and okadaic acid to study Alzheimer’s disease. Neural Regen Res  2018; 13(9): 1538-41.
 [http://dx.doi.org/10.4103/1673-5374.237111] [PMID: 30127109]

[55]
Sontag JM, Sontag E. Protein phosphatase 2A dysfunction in Alzheimer’s disease. Front Mol Neurosci  2014; 7: 16.
 [PMID: 24653673]

[56]
Nada SE, Williams FE, Shah ZA. Development of a novel and robust pharmacological model of okadaic acid-induced alzheimer’s disease in zebrafish. CNS Neurol Disord Drug Targets  2016; 15(1): 86-94.
 [http://dx.doi.org/10.2174/1871527314666150821105602] [PMID: 26295819]

[57]
Cacialli P, Gueguen MM, Coumailleau P, et al. BDNF expression in larval and adult zebrafish brain: Distribution and cell identification. PLoS One  2016; 11(6): e0158057.
 [http://dx.doi.org/10.1371/journal.pone.0158057] [PMID: 27336917]

[58]
Koehler D, Shah ZA, Hensley K, Williams FE. Lanthionine ketimine-5-ethyl ester provides neuroprotection in a zebrafish model of okadaic acid-induced Alzheimer’s disease. Neurochem Int  2018; 115: 61-8.
 [http://dx.doi.org/10.1016/j.neuint.2018.02.002] [PMID: 29475037]

[59]
Koehler D, Shah ZA, Williams FE. The GSK3β inhibitor, TDZD-8, rescues cognition in a zebrafish model of okadaic acid-induced Alzheimer’s disease. Neurochem Int  2019; 122: 31-7.
 [http://dx.doi.org/10.1016/j.neuint.2018.10.022] [PMID: 30392874]

[60]
Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med  2011; 1(1): a006189.
 [http://dx.doi.org/10.1101/cshperspect.a006189] [PMID: 22229116]

[61]
Johnson GVW, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci  2004; 117(24): 5721-9.
 [http://dx.doi.org/10.1242/jcs.01558] [PMID: 15537830]

[62]
Medina M, Avila J, Villanueva N. Use of okadaic acid to identify relevant phosphoepitopes in pathology: A focus on neurodegeneration. Mar Drugs  2013; 11(5): 1656-68.
 [http://dx.doi.org/10.3390/md11051656]

[63]
Ryu AR, Kim DH, Kim E, Lee MY. Use of okadaic acid to identify relevant phosphoepitopes in pathology: A focus on neurodegeneration. Mar Drugs  2018; 11(5): 1656-568.
 [http://dx.doi.org/10.1155/2018/4692081]

[64]
Naik P, Fofaria N, Prasad S, et al. Oxidative and pro-inflammatory impact of regular and denicotinized cigarettes on blood brain barrier endothelial cells: Is smoking reduced or nicotine-free products really safe? BMC Neurosci  2014; 15(1): 51.
 [http://dx.doi.org/10.1186/1471-2202-15-51] [PMID: 24755281]

[65]
Naik P, Sajja RK, Prasad S, Cucullo L. Effect of full flavor and denicotinized cigarettes exposure on the brain microvascular endothelium: A microarray-based gene expression study using a human immortalized BBB endothelial cell line. BMC Neurosci  2015; 16(1): 38.
 [http://dx.doi.org/10.1186/s12868-015-0173-3] [PMID: 26099276]

[66]
Alrouji M, Manouchehrinia A, Gran B, Constantinescu CS. Effects of cigarette smoke on immunity, neuroinflammation and multiple sclerosis. J Neuroimmunol  2019; 329: 24-34.
 [http://dx.doi.org/10.1016/j.jneuroim.2018.10.004] [PMID: 30361070]

[67]
Aedo G, Miranda M, Chávez MN, Allende ML, Egaña JT. A reliable preclinical model to study the impact of cigarette smoke in development and disease. Curr Protoc Toxicol  2019; 80(1): e78.
 [http://dx.doi.org/10.1002/cptx.78] [PMID: 31058471]

[68]
Muthuraman A, Thilagavathi L, Jabeen S, Ravishankar SB, Ahmed SS, George T. Curcumin prevents cigarette smoke extract induced cognitive impairment. Front Biosci  2019; 11(1): 109-20.
 [http://dx.doi.org/10.2741/e850]

[69]
Muthuraman A, Nafisa K, Sowmya MS, et al. Role of ambrisentan (selective endothelin-A receptor antagonist) on cigarette smoke exposure induced cognitive impairment in Danio rerio. Life Sci  2019; 222: 133-9.
 [http://dx.doi.org/10.1016/j.lfs.2019.03.002] [PMID: 30844374]

[70]
Paduraru E, Iacob D, Rarinca V, Plavan G, Ureche D, Jijie R. Zebrafish as a potential model for neurodegenerative diseases: A focus on toxic metals implications. Int J Mol Sci  2023; 24(4): 3428.
 [http://dx.doi.org/10.3390/ijms24043428]

[71]
Lopes AC, Peixe TS, Mesas AE, Paoliello MMB. Lead exposure and oxidative stress: A systematic review. Rev Environ Contam Toxicol  2016; 236: 193-238.
 [PMID: 26423075]

[72]
Rossi E. Low level environmental lead exposure – a continuing challenge. Clin Biochem Rev  2008; 29(2): 63.

[73]
Mansouri MT, Muñoz-Fambuena I, Cauli O. Cognitive impairment associated with chronic lead exposure in adults. Neurol Psychiatry Brain Res  2018; 30: 5-8.
 [http://dx.doi.org/10.1016/j.npbr.2018.04.001]

[74]
Mu Y, Yu J, Ji W, Chen L, Wang X, Yan B. Alleviation of Pb2+ pollution-induced oxidative stress and toxicity in microglial cells and zebrafish larvae by chicoric acid. Ecotoxicol Environ Saf  2019; 180: 396-402.
 [http://dx.doi.org/10.1016/j.ecoenv.2019.05.040] [PMID: 31108416]

[75]
Tisato F, Marzano C, Porchia M, Pellei M, Santini C. Copper in diseases and treatments, and copper-based anticancer strategies. Med Res Rev  2010; 30(4): 708-49.
 [http://dx.doi.org/10.1002/med.20174] [PMID: 19626597]

[76]
Huffman DL, O’Halloran TV. Energetics of copper trafficking between the Atx1 metallochaperone and the intracellular copper transporter, Ccc2. J Biol Chem  2000; 275(25): 18611-4.
 [http://dx.doi.org/10.1074/jbc.C000172200] [PMID: 10764731]

[77]
Labbé S, Zhu Z, Thiele DJ. Copper-specific transcriptional repression of yeast genes encoding critical components in the copper transport pathway. J Biol Chem  1997; 272(25): 15951-8.
 [http://dx.doi.org/10.1074/jbc.272.25.15951] [PMID: 9188496]

[78]
Mackenzie NC, Brito M, Reyes AE, Allende ML. Cloning, expression pattern and essentiality of the high-affinity copper transporter 1 (ctr1) gene in zebrafish. Gene  2004; 328(1–2): 113-20.
 [http://dx.doi.org/10.1016/j.gene.2003.11.019] [PMID: 15019990]

[79]
Bellingham SA, Ciccotosto GD, Needham BE, et al. Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. J Neurochem  2004; 91(2): 423-8.
 [http://dx.doi.org/10.1111/j.1471-4159.2004.02731.x] [PMID: 15447675]

[80]
Tõugu V, Tiiman A, Palumaa P. Interactions of Zn(ii) and Cu(ii) ions with Alzheimer’s amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity. Metallomics  2011; 3(3): 250-61.
 [http://dx.doi.org/10.1039/c0mt00073f] [PMID: 21359283]

[81]
Xiao T, Ackerman CM, Carroll EC, Jia S, Hoagland A, Chan J. Copper regulates rest-activity cycles through the locus coeruleus-norepinephrine system. Nat Chem Biol  2018; 14: 655-63.
 [http://dx.doi.org/10.1038/s41589-018-0062-z]

[82]
Crouch PJ, Hung LW, Adlard PA, et al. Increasing Cu bioavailability inhibits Aβ oligomers and tau phosphorylation. Proc Natl Acad Sci  2009; 106(2): 381-6.
 [http://dx.doi.org/10.1073/pnas.0809057106] [PMID: 19122148]

[83]
Rihel J. Copper on the brain. Nat Chem Biol  2018; 14(7): 638-9.
 [http://dx.doi.org/10.1038/s41589-018-0089-1]

[84]
McLaughlin AIG, Kazantzis G, King E, Teare D, Porter RJ, Owen R. Pulmonary fibrosis and encephalopathy associated with the inhalation of aluminium dust. Occup Environ Med  1962; 19(4): 253-63.
 [http://dx.doi.org/10.1136/oem.19.4.253]

[85]
Crapper DR, Krishnan SS, Dalton AJ. Distribution in alzheimer’s disease and experimental neurofibrillary degeneration. Science  1979; 180(4085): 511-3.

[86]
Bondy SC. Low levels of aluminum can lead to behavioral and morphological changes associated with Alzheimer’s disease and age-related neurodegeneration. Neurotoxicology  2016; 52: 222-9.
 [http://dx.doi.org/10.1016/j.neuro.2015.12.002] [PMID: 26687397]

[87]
Wang Z, Wei X, Yang J, et al. Chronic exposure to aluminum and risk of Alzheimer’s disease: A meta-analysis. Neurosci Lett  2016; 610: 200-6.
 [http://dx.doi.org/10.1016/j.neulet.2015.11.014] [PMID: 26592479]

[88]
Dave G. The influence of pH on the toxicity of aluminum, cadmium, and iron to eggs and larvae of the zebrafish, Brachydanio rerio. Ecotoxicol Environ Saf  1985; 10(2): 253-67.
 [http://dx.doi.org/10.1016/0147-6513(85)90072-7] [PMID: 4085384]

[89]
Monaco A, Grimaldi MC, Ferrandino I. Aluminium chloride-induced toxicity in zebrafish larvae. J Fish Dis  2017; 40(5): 629-35.
 [http://dx.doi.org/10.1111/jfd.12544] [PMID: 27523735]

[90]
Xiong H, Zhao-Ming Z, Yi C, Xiong H, Zhao-Ming Z, Yi C. Locomotor activity and learning and memory abilities in Alzheimer’s disease induced by aluminum in an acid environment in zebrafish. Dongwuxue Yanjiu  2012; 33(2): 231-6.

[91]
Senger MR, Seibt KJ, Ghisleni GC, Dias RD, Bogo MR, Bonan CD. Aluminum exposure alters behavioral parameters and increases acetylcholinesterase activity in zebrafish (Danio rerio) brain. Cell Biol Toxicol  2011; 27(3): 199-205.
 [http://dx.doi.org/10.1007/s10565-011-9181-y] [PMID: 21240652]

[92]
Chiswell B, Mokhtar MB. The speciation of manganese in freshwaters. Talanta  1986; 33(8): 669-77.
 [http://dx.doi.org/10.1016/0039-9140(86)80156-4] [PMID: 18964165]

[93]
Lee E, Karki P, Johnson J Jr, Hong P, Aschner M. Manganese control of glutamate transporters’ gene expression. Adv Neurobiol  2017; 16: 1-12.
 [http://dx.doi.org/10.1007/978-3-319-55769-4_1] [PMID: 28828603]

[94]
Harford AJ, Mooney TJ, Trenfield MA, van Dam RA. Manganese toxicity to tropical freshwater species in low hardness water. Environ Toxicol Chem  2015; 34(12): 2856-63.
 [http://dx.doi.org/10.1002/etc.3135] [PMID: 26118763]

[95]
Peres TV, Schettinger MRC, Chen P, Carvalho F, Avila DS, Bowman AB. Manganese-induced neurotoxicity: A review of its behavioral consequences and neuroprotective strategies. BMC Pharmacol Toxicol  2016; 17: 57.
 [http://dx.doi.org/10.1186/s40360-016-0099-0]

[96]
Tuschl K, Mills PB, Clayton PT. Manganese and the Brain. Int Rev Neurobiol  2013; 110: 277-312.
 [http://dx.doi.org/10.1016/B978-0-12-410502-7.00013-2] [PMID: 24209443]

[97]
Horning KJ, Caito SW, Tipps KG, Bowman AB, Aschner M. Manganese is essential for neuronal health. Annu Rev Nutr  2015; 35: 71-108.
 [http://dx.doi.org/10.1146/annurev-nutr-071714-034419]

[98]
Chen P, Miah MR, Aschner M. Metals and neurodegeneration. F1000Res   2016; 5: F1000 Faculty Rev-366.

[99]
Kim H, Harrison FE, Aschner M, Bowman AB. Exposing the role of metals in neurological disorders: A focus on manganese. Trends Mol Med  2022; 28(7): 555-68.
 [http://dx.doi.org/10.1016/j.molmed.2022.04.011] [PMID: 35610122]

[100]
Altenhofen S, Wiprich MT, Nery LR, Leite CE, Vianna MRMR, Bonan CD. Manganese(II) chloride alters behavioral and neurochemical parameters in larvae and adult zebrafish. Aquat Toxicol  2017; 182: 172-83.
 [http://dx.doi.org/10.1016/j.aquatox.2016.11.013] [PMID: 27912164]

[101]
Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol  2014; 13(10): 1045-60.
 [http://dx.doi.org/10.1016/S1474-4422(14)70117-6] [PMID: 25231526]

[102]
Ashraf A, So PW. Spotlight on ferroptosis: Iron-dependent cell death in alzheimer’s disease. Front Aging Neurosci  2020; 12: 196.
 [http://dx.doi.org/10.3389/fnagi.2020.00196] [PMID: 32760266]

[103]
Wang F, Wang J, Shen Y, Li H, Rausch WD, Huang X. Iron dyshomeostasis and ferroptosis: A new Alzheimer’s Disease hypothesis? Front Aging Neurosci  2022; 14: 830569.
 [http://dx.doi.org/10.3389/fnagi.2022.830569] [PMID: 35391749]

[104]
Peng Y, Chang X, Lang M. Iron homeostasis disorder and alzheimer’s disease. Int J Mol Sci  2021; 22(22): 12442.
 [http://dx.doi.org/10.3390/ijms222212442]

[105]
Cassidy L, Fernandez F, Johnson JB, Naiker M, Owoola AG, Broszczak DA. Oxidative stress in alzheimer’s disease: A review on emergent natural polyphenolic therapeutics. Complement Ther Med  2020; 49: 102294.
 [http://dx.doi.org/10.1016/j.ctim.2019.102294] [PMID: 32147039]

[106]
Acosta DS, Danielle NM, Altenhofen S, et al. Copper at low levels impairs memory of adult zebrafish (Danio rerio) and affects swimming performance of larvae. Comp Biochem Physiol C Toxicol Pharmacol  2016; 185-186: 122-30.
 [http://dx.doi.org/10.1016/j.cbpc.2016.03.008] [PMID: 27012768]

[107]
Haverroth GMB, Welang C, Mocelin RN, et al. Copper acutely impairs behavioral function and muscle acetylcholinesterase activity in zebrafish (Danio rerio). Ecotoxicol Environ Saf  2015; 122: 440-7.
 [http://dx.doi.org/10.1016/j.ecoenv.2015.09.012] [PMID: 26386335]

[108]
Xu X, Weber D, Burge R, VanAmberg K. Neurobehavioral impairments produced by developmental lead exposure persisted for generations in zebrafish (Danio rerio). Neurotoxicology  2016; 52: 176-85.
 [http://dx.doi.org/10.1016/j.neuro.2015.12.009] [PMID: 26688331]

[109]
Zhu B, Wang Q, Shi X, Guo Y, Xu T, Zhou B. Effect of combined exposure to lead and decabromodiphenyl ether on neurodevelopment of zebrafish larvae. Chemosphere  2016; 144: 1646-54.
 [http://dx.doi.org/10.1016/j.chemosphere.2015.10.056] [PMID: 26519795]

[110]
Cras P, Kawai M, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Perry G. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc Natl Acad Sci  1991; 88(17): 7552-6.
 [http://dx.doi.org/10.1073/pnas.88.17.7552] [PMID: 1652752]

[111]
Bai Q, Burton EA. Zebrafish models of Tauopathy. Biochim Biophys Acta Mol Basis Dis  2011; 1812(3): 353-63.
 [http://dx.doi.org/10.1016/j.bbadis.2010.09.004]

[112]
Weber T, Köster R. Genetic tools for multicolor imaging in zebrafish larvae. Methods  2013; 62(3): 279-91.
 [http://dx.doi.org/10.1016/j.ymeth.2013.07.028] [PMID: 23886907]

[113]
Lee JA, Cole GJ. Generation of transgenic zebrafish expressing green fluorescent protein under control of zebrafish amyloid precursor protein gene regulatory elements. Zebrafish  2007; 4(4): 277-86.
 [http://dx.doi.org/10.1089/zeb.2007.0516] [PMID: 18284334]

[114]
Shakes LA, Malcolm TL, Allen KL, De S, Harewood KR, Chatterjee PK. Context dependent function of APPb enhancer identified using enhancer trap-containing BACs as transgenes in zebrafish. Nucleic Acids Res  2008; 36(19): 6237-48.
 [http://dx.doi.org/10.1093/nar/gkn628] [PMID: 18832376]

[115]
Nik SH, Wilson L, Newman M, et al. The BACE1-PSEN-AβPP regulatory axis has an ancient role in response to low oxygen/oxidative stress. J Alzheimers Dis  2012; 28(3): 515-30.
 [http://dx.doi.org/10.3233/JAD-2011-110533] [PMID: 22045484]

[116]
Pu YZ, Liang L, Fu AL, et al. Generation of Alzheimer’s disease transgenic zebrafish expressing human app mutation under control of zebrafish appb promotor. Curr Alzheimer Res  2017; 14(6): 668-79.
 [http://dx.doi.org/10.2174/1567205013666161201202000] [PMID: 27978793]

[117]
Cameron DJ, Galvin C, Alkam T, Sidhu H, Ellison J, Luna S. Alzheimer’s-related peptide amyloid-β plays a conserved role in angiogenesis. PLoS One  2012; 7(7): e39598.

[118]
Cunvong K, Huffmire D, Ethell DW, Cameron DJ. Amyloid-β increases capillary bed density in the adult zebrafish retina. Invest Ophthalmol Vis Sci  2013; 54(2): 1516-21.
 [http://dx.doi.org/10.1167/iovs.12-10821] [PMID: 23404118]

[119]
McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C A. Aβ42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron  2005; 47(2): 191.
 [http://dx.doi.org/10.1016/j.neuron.2005.06.030]

[120]
Meyer EP, Ulmann-Schuler A, Staufenbiel M, Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer’s disease. Proc Natl Acad Sci  2008; 105(9): 3587.

[121]
Hannan SB, Dräger NM, Rasse TM, Voigt A, Jahn TR. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models. J Neurochem  2016; 137(1): 12-25.
 [http://dx.doi.org/10.1111/jnc.13532] [PMID: 26756400]

[122]
Liu Y. Zebrafish as a model organism for studying pathologic mechanisms of neurodegenerative diseases and other neural disorders. Cell Mol Neurobiol  2023; 43(6): 2603-20.
 [http://dx.doi.org/10.1007/s10571-023-01340-w]

[123]
De Strooper B, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature  1998; 391(6665): 387-90.
 [http://dx.doi.org/10.1038/34910] [PMID: 9450754]

[124]
Paquet D, Schmid B, Haass C. Transgenic zebrafish as a novel animal model to study tauopathies and other neurodegenerative disorders in vivo. Neurodegener Dis  2010; 7(1-3): 99-102.
 [http://dx.doi.org/10.1159/000285515] [PMID: 20173336]

[125]
De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and γ-secretase: Structure, function, and role in alzheimer disease. Cold Spring Harb Perspect Med  2012; 2(1)

[126]
Bentahir M, Nyabi O, Verhamme J, et al. Presenilin clinical mutations can affect γ-secretase activity by different mechanisms. J Neurochem  2006; 96(3): 732-42.
 [http://dx.doi.org/10.1111/j.1471-4159.2005.03578.x] [PMID: 16405513]

[127]
Barbier P, Zejneli O, Martinho M, et al. Role of tau as a microtubule-associated protein: Structural and functional aspects. Front Aging Neurosci  2019; 11: 204.
 [http://dx.doi.org/10.3389/fnagi.2019.00204] [PMID: 31447664]

[128]
Takashima A, Murayama M, Murayama O, et al. Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau. Proc Natl Acad Sci  1998; 95(16): 9637-41.
 [http://dx.doi.org/10.1073/pnas.95.16.9637] [PMID: 9689133]

[129]
Köpke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem  1993; 268(32): 24374-84.
 [http://dx.doi.org/10.1016/S0021-9258(20)80536-5] [PMID: 8226987]

[130]
Flament S, Delacourte A, Verny M, Hauw JJ, Javoy-Agid F. Abnormal Tau proteins in progressive supranuclear palsy. Acta Neuropathol  1991; 81(6): 591-6.
 [http://dx.doi.org/10.1007/BF00296367] [PMID: 1831952]

[131]
Andreadis A. Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim Biophys Acta Mol Basis Dis  2005; 1739(2-3): 91-103.
 [http://dx.doi.org/10.1016/j.bbadis.2004.08.010] [PMID: 15615629]

[132]
Barbereau C, Cubedo N, Maurice T, Rossel M. Zebrafish models to study new pathways in tauopathies. Int J Mol Sci  2021; 22(9): 4626.
 [http://dx.doi.org/10.3390/ijms22094626]

[133]
Nery LR, Silva NE, Fonseca R, Vianna MRM. Presenilin-1 targeted morpholino induces cognitive deficits, increased brain aβ1-42 and decreased synaptic marker psd-95 in zebrafish larvae. Neurochem Res  2017; 42(10): 2959-67.
 [http://dx.doi.org/10.1007/s11064-017-2327-4] [PMID: 28623607]

[134]
Nornes S, Groth C, Camp E, Ey P, Lardelli M. Developmental control of Presenilin1 expression, endoproteolysis, and interaction in zebrafish embryos. Exp Cell Res  2003; 289(1): 124-32.
 [http://dx.doi.org/10.1016/S0014-4827(03)00257-X] [PMID: 12941610]

[135]
Sharma P, Saraswathy VM, Xiang L, Fürthauer M. Notch-mediated inhibition of neurogenesis is required for zebrafish spinal cord morphogenesis. Sci Rep  2019; 9(1): 9958.
 [http://dx.doi.org/10.1038/s41598-019-46067-1]

[136]
Geling A, Steiner H, Willem M, Bally-Cuif L, Haass C A. A γ‐ secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep  2002; 3(7): 688-94.
 [http://dx.doi.org/10.1093/embo-reports/kvf124] [PMID: 12101103]

[137]
Pigino G, Pelsman A, Mori H, Busciglio J. Presenilin-1 mutations reduce cytoskeletal association, deregulate neurite growth, and potentiate neuronal dystrophy and tau phosphorylation. J Neurosci  2001; 21(3): 834-42.
 [http://dx.doi.org/10.1523/JNEUROSCI.21-03-00834.2001] [PMID: 11157069]

[138]
Nornes S, Newman M, Wells S, Verdile G, Martins RN, Lardelli M. Independent and cooperative action of Psen2 with Psen1 in zebrafish embryos. Exp Cell Res  2009; 315(16): 2791-801.
 [http://dx.doi.org/10.1016/j.yexcr.2009.06.023] [PMID: 19563801]

[139]
Barazzuol L, Cieri D, Facchinello N, et al. Unraveling presenilin 2 functions in a knockout zebrafish line to shed light into alzheimer’s disease pathogenesis. Cells  2023; 12(3): 376.
 [http://dx.doi.org/10.3390/cells12030376] [PMID: 36766721]

[140]
Weller J, Budson A. Current understanding of Alzheimer’s disease diagnosis and treatment.  F1000Res   2018; 7: F1000 Faculty Rev- 1161.

[141]
Dong Y, Newman M, Pederson SM, Barthelson K, Hin N, Lardelli M. Transcriptome analyses of 7-day-old zebrafish larvae possessing a familial Alzheimer’s disease-like mutation in psen1 indicate effects on oxidative phosphorylation, ECM and MCM functions, and iron homeostasis. BMC Genomics  2021; 22(1): 211.
 [http://dx.doi.org/10.1186/s12864-021-07509-1] [PMID: 33761877]

[142]
Howe K, Clark MD, Torroja CF, et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature  2013; 496(7446): 498-503.
 [http://dx.doi.org/10.1038/nature12111] [PMID: 23594743]

[143]
van Tijn P, Kamphuis W, Marlatt MW, Hol EM, Lucassen PJ. Presenilin mouse and zebrafish models for dementia: Focus on neurogenesis. Prog Neurobiol  2011; 93(2): 149-64.
 [http://dx.doi.org/10.1016/j.pneurobio.2010.10.008] [PMID: 21056616]

[144]
Delabio R, Rasmussen L, Mizumoto I, et al. PSEN1 and PSEN2 gene expression in Alzheimer’s disease brain: a new approach. J Alzheimers Dis  2014; 42(3): 757-60.
 [http://dx.doi.org/10.3233/JAD-140033] [PMID: 24927704]

[145]
Hin N, Newman M, Kaslin J, et al. Accelerated brain aging towards transcriptional inversion in a zebrafish model of the K115fs mutation of human PSEN2. PLoS One  2020; 15(1): e0227258.
 [http://dx.doi.org/10.1371/journal.pone.0227258] [PMID: 31978074]

[146]
Lanoiselée HM, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med  2017; 14(3): e1002270.

[147]
Musa A, Lehrach H, Russo V. Distinct expression patterns of two zebrafish homologues of the human APP gene during embryonic development. Dev Genes Evol  2001; 211(11): 563-7.
 [http://dx.doi.org/10.1007/s00427-001-0189-9] [PMID: 11862463]

[148]
Durliat M, André M, Babin PJ. Conserved protein motifs and structural organization of a fish gene homologous to mammalian apolipoprotein E. Eur J Biochem  2000; 267(2): 549-59.
 [http://dx.doi.org/10.1046/j.1432-1327.2000.01033.x] [PMID: 10632725]

[149]
Lee J, Peterson SM, Freeman JL. Alzheimer’s disease risk genes in wild-type adult zebrafish exhibit gender-specific expression changes during aging. Neurogenetics  2016; 17(3): 197-9.
 [http://dx.doi.org/10.1007/s10048-016-0485-1] [PMID: 27234028]

[150]
van Bebber F, Hruscha A, Willem M, Schmid B, Haass C. Loss of Bace2 in zebrafish affects melanocyte migration and is distinct from Bace1 knock out phenotypes. J Neurochem  2013; 127(4): 471-81.
 [http://dx.doi.org/10.1111/jnc.12198] [PMID: 23406323]

[151]
Campbell WA, Yang H, Zetterberg H, et al. Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss. J Neurochem  2006; 96(5): 1423-40.
 [http://dx.doi.org/10.1111/j.1471-4159.2006.03648.x] [PMID: 16464238]

[152]
Francis R, McGrath G, Zhang J, et al. aph-1 and pen-2 are required for Notch pathway signaling, γ-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell  2002; 3(1): 85-97.
 [http://dx.doi.org/10.1016/S1534-5807(02)00189-2] [PMID: 12110170]

[153]
Lim A, Nik SH, Ebrahimie E, Lardelli M. Analysis of nicastrin gene phylogeny and expression in zebrafish. Dev Genes Evol  2015; 225(3): 171-8.
 [http://dx.doi.org/10.1007/s00427-015-0500-9] [PMID: 25940938]

[154]
Leimer U, Lun K, Romig H, et al. Zebrafish (Danio rerio) presenilin promotes aberrant amyloid β-peptide production and requires a critical aspartate residue for its function in amyloidogenesis. Biochemistry  1999; 38(41): 13602-9.
 [http://dx.doi.org/10.1021/bi991453n] [PMID: 10521267]

[155]
Groth C, Nornes S, McCarty R, Tamme R, Lardelli M. Identification of a second presenilin gene in zebrafish with similarity to the human Alzheimer’s disease gene presenilin2. Dev Genes Evol  2002; 212(10): 486-90.
 [http://dx.doi.org/10.1007/s00427-002-0269-5] [PMID: 12424519]

[156]
Lee J, Peterson SM, Freeman JL. Sex-specific characterization and evaluation of the Alzheimer’s disease genetic risk factor sorl1 in zebrafish during aging and in the adult brain following a 100 ppb embryonic lead exposure. J Appl Toxicol  2017; 37(4): 400-7.
 [http://dx.doi.org/10.1002/jat.3372] [PMID: 27535807]

[157]
Strang KH, Golde TE, Giasson BI. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab Invest  2019; 99(7): 912-28.
 [http://dx.doi.org/10.1038/s41374-019-0197-x] [PMID: 30742061]

[158]
Dib S, Pahnke J, Gosselet F. Role of ABCA7 in human health and in alzheimer’s disease. Int J Mol Sci  2021; 22(9): 4603.
 [http://dx.doi.org/10.3390/ijms22094603]
Rights & Permissions Print Cite
Article Metrics
32
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0127724328279684240104094257	Print ISSN 2772-4328
Publisher Name Bentham Science Publisher	Online ISSN 2772-4336
Current Reviews in Clinical and Experimental Pharmacology

Zebrafish Experimental Animal Models for AD: A Comprehensive Review

Abstract

Graphical Abstract

Current Reviews in Clinical and Experimental Pharmacology

Zebrafish Experimental Animal Models for AD: A Comprehensive Review

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles
